Prophylactic administration of IFN-γ along with antimicrobial agents remains a mainstay of treatment for the disorder [15,17–21], yet the mechanism(s) by which IFN-γ achieves its clinical effects in CGD are not completely understood. This evidence concerns the gene IFNG and chronic granulomatous disease.